Prospective study of sex hormone levels and risk of prostate cancer

Journal of the National Cancer Institute

Volumn 88, Issue 16, 1996, Pages 1118-1126

  Gann, Peter H ^a,b   Hennekens, Charles H ^a,c,d   Ma, Jing ^a   Longcope, Christopher ^e   Stampfer, Meir J ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANEDIOL; ANDROSTANOLONE; ESTRADIOL; PROLACTIN; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ARTICLE; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ESTRADIOL BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; RISK ASSESSMENT; TESTOSTERONE BLOOD LEVEL;

EID: 0029813882     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.16.1118     Document Type: Article

References (35)

1. Henderson BE, Ross RK, Pike MC, Casagrande JT. Endogenous hormones as a major factor in human cancer. Cancer Res 1982;42:3232-9.
2. Noble RL. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 1977;37:1929-33.
3. Huggins C, Hodges CV. Studies on prostate cancer: effect of castration, of estrogen, and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
4. Glantz CM. Cirrhosis and carcinoma of the prostate gland. J Urol 1964;91:291-3.
5. Nomura AM, Kolonel LN. Prostate cancer: a current perspective. Epidemiol Rev 1991;13:200-27.
6. Meikle AW, Smith JA Jr. Epidemiology of prostate cancer. Urol Clin North Am 1990;17:709-18.
7. Kovacs WJ, Griffin JE, Wilson JD. Transformation of human androgen receptors to the deoxyribonucleic acid-binding state. Endocrinology 1983; 113:1574-81.
8. Horton R, Hawks D, Lobo R. 3 Alpha, 17 beta-androstanediol glucuronide in plasma. A marker of androgen action in idiopathic hirsutism. J Clin Invest 1982;69:1203-6.
9. Brawley OW, Ford LG, Thompson I, Perlman JA, Kramer BS. 5-Alpha-reductase inhibition and prostate cancer prevention. Cancer Epidemiol Biomarkers Prev 1994;3:177-82.
10. Rosner W. The functions of corticosteroid-binding globulin and sex hormone-binding globulin: recent advances. Endocr Rev 1990;11:80-91.
11. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group [see comment citations in Medline]. N Engl J Med 1989;321:129-35.
12. Longcope C, Franz C, Morello C, Baker R, Johnston CC Jr. Steroid and gonadotropin levels in women during the peri-menopausal years. Maturitas 1986;8:189-96.
13. Gittes RF. Carcinoma of the prostate [see comment citation in Medline]. N Engl J Med 1991;324:236-45.
14. Catalona WJ, Avioli LV. Diagnosis, staging, and surgical treatment of prostatic carcinoma. Arch Intern Med 1987;147:361-3.
15. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, et al. Results of conservative management of clinically localized prostate cancer [see comment citations in Medline]. N Engl J Med 1994; 330:242-8.
16. Pasquali R, Casimirri F, Cantobelli S, Melchionda N, Morselli Labate AM, Fabbri R, et al. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism 1991;40:101-4.
17. Garfinkel L. Overweight and mortality. Cancer 1986;58:1826-9.
18. Meikle AW, Smith JA, Stringham JD. Production, clearance, and metabolism of testosterone in men with prostatic cancer. Prostate 1987;10:25-31.
19. Harper ME, Wilson DW, Jensen HM, Pierrepoint CG, Griffiths K. Steroid hormone concentrations in relation to patient prognosis and prostate tumour grade. J Steroid Biochem 1987;27:521-4.
20. Barrett-Connor E, Garland C, McPhillips JB, Khaw KT, Wingard DL. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res 1990;50:169-73.
21. Nomura A, Heilbrun LK, Stemmermann GN, Judd HL. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 1988;48:3515-7.
22. Hsing AW, Comstock GW. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev 1993;2:27-32.
23. Rannikko S, Adlercreutz H. Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer. Prostate 1983;4:223-9.
24. Siiteri PK, Simberg NH. Changing concepts of active androgens in blood. Clin Endocrinol Metab 1986;15:247-58.
25. Mendel CM. The free hormone hypothesis: a physiologically based mathematical model. Endocr Rev 1989;10:232-74.
26. Longcope C. Goldfield SR, Brambilla DJ, McKinlay JB. Androgens, estrogens, and sex hormone-binding globulin in middle-aged men. J Clin Endocrinol Metab 1990;71:1442-6.
27. Anderson DC. Sex hormone-binding globulin. Clin Endocrinol 1974;3:69-96.
28. Gann PH, Hennekens CH, Longcope C, Verhoek-Oftedahl W, Grodstein F, Stampfer MJ. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate 1995:26:40-9.
29. Huggins C, Webster WO. Duality of human prostate in response to estrogen. J Urol 1948:59:258-66.
30. Wilson JD, Aiman J, MacDonald PC. The pathogenesis of gynecomastia. Adv Intern Med 1980;25:1-32.
31. Burke CW, Anderson DC. Sex-hormone-binding globulin is an oestrogen amplifier. Nature 1972;240:38-40.
32. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC, et al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992;339:887-9.
33. Meikle AW, Smith JA, Stringham JD. Estradiol and testosterone metabolism and production in men with prostatic cancer. J Steroid Biochem 1989;33:19-24.
34. Bain J, Langevin R, D'Costa M, Sanders RM, Hucker S. Serum pituitary and steroid hormone levels in the adult male: one value is as good as the mean of three. Fertil Steril 1988;49:123-6.
35. Vermeulen A, Verdonck G. Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men. J Clin Endocrinol Metab 1992;74:939-42.